The Australian medical landscape is abuzz with the introduction of retatrutide, a groundbreaking dual GIP and GLP-1 receptor agonist showing impressive results in early trials for managing obesity. This https://ztndz.com/story29288410/retatrutide-australia-australia-a-new-hope-for-obesity-treatment